CA2171955A1 - Composition pharmaceutique renfermant des anticorps monoclonaux anti-recepteur de l'interferon, avec action neutralisante contre l'interferon de type i - Google Patents

Composition pharmaceutique renfermant des anticorps monoclonaux anti-recepteur de l'interferon, avec action neutralisante contre l'interferon de type i

Info

Publication number
CA2171955A1
CA2171955A1 CA002171955A CA2171955A CA2171955A1 CA 2171955 A1 CA2171955 A1 CA 2171955A1 CA 002171955 A CA002171955 A CA 002171955A CA 2171955 A CA2171955 A CA 2171955A CA 2171955 A1 CA2171955 A1 CA 2171955A1
Authority
CA
Canada
Prior art keywords
ifn
human
pharmaceutical composition
anyone
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002171955A
Other languages
English (en)
Inventor
Michael G. Tovey
Eric Jacob Benizri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE SA filed Critical LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE SA
Publication of CA2171955A1 publication Critical patent/CA2171955A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des compositions pharmaceutiques utilisées en tant qu'immunomodulateurs, comprenant une préparation purifiée d'un anticorps monoclonal dirigé contre le récepteur d'interféron humain de la classe I (IFN-R), et caractérisées par les propriétés suivantes: reconnaissance du domaine extracellulaire de l'INF-R humain, et capacité de neutralisation dressée contre les propriétés biologiques de l'I-IFN de type humain. On a également prévu leur utilisation diagnostique.
CA002171955A 1993-09-17 1994-09-16 Composition pharmaceutique renfermant des anticorps monoclonaux anti-recepteur de l'interferon, avec action neutralisante contre l'interferon de type i Abandoned CA2171955A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93402279 1993-09-17
EP93402279.9 1993-09-17

Publications (1)

Publication Number Publication Date
CA2171955A1 true CA2171955A1 (fr) 1995-03-23

Family

ID=8214749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002171955A Abandoned CA2171955A1 (fr) 1993-09-17 1994-09-16 Composition pharmaceutique renfermant des anticorps monoclonaux anti-recepteur de l'interferon, avec action neutralisante contre l'interferon de type i

Country Status (5)

Country Link
EP (1) EP0725654A1 (fr)
JP (1) JPH11501283A (fr)
AU (1) AU7782894A (fr)
CA (1) CA2171955A1 (fr)
WO (1) WO1995007716A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
WO2002067760A2 (fr) * 2001-01-09 2002-09-06 Baylor Research Institute Traitements de maladies auto-immunes chez un sujet et techniques diagnostiques in vitro
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
AU2007203559B2 (en) * 2003-04-23 2010-09-02 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
US7619070B2 (en) * 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
CA2823468A1 (fr) * 2003-04-23 2004-11-04 Medarex, L.L.C. Compositions et techniques destinees a la therapie d'une maladie intestinale inflammatoire
PT1711207E (pt) 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
PL1781705T3 (pl) 2004-06-21 2015-03-31 Squibb & Sons Llc Antyciała receptora interferonów alfa I oraz ich zastosowania

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
FR2653445B1 (fr) * 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
DE69214656T2 (de) * 1991-08-30 1997-03-13 Genentech Inc Therapeutisches verfahren zur behandlung von iddm
EP0563487A1 (fr) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I

Also Published As

Publication number Publication date
AU7782894A (en) 1995-04-03
EP0725654A1 (fr) 1996-08-14
WO1995007716A1 (fr) 1995-03-23
JPH11501283A (ja) 1999-02-02

Similar Documents

Publication Publication Date Title
US7179465B2 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon
JP2755395B2 (ja) Ｈｉｖ感染細胞に殺作用する抗体異種結合体
CA2038279C (fr) Molecules fixatrices de cd25
WO1998042377A1 (fr) Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
JP4308322B2 (ja) インターフェロンアルファ／ベータ受容体に対する抗体
JPH05505112A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
CN1780907B (zh) 抗ccr5抗体
CA2171955A1 (fr) Composition pharmaceutique renfermant des anticorps monoclonaux anti-recepteur de l'interferon, avec action neutralisante contre l'interferon de type i
JP2000511775A (ja) Ｃｄ４とケモカイン受容体領域の複合体に対する抗体、及びｈｉｖ感染に対するそれらの利用
JP3104187B2 (ja) インターフエロン―ガンマ結合蛋白
JP2003507011A (ja) Ｉｌ−１６拮抗剤
Looney et al. High-level expression and characterization of a mouse-human chimeric CD4 antibody with therapeutic potential
US7510715B2 (en) Protozoan derived compositions and methods of use thereof
Rosenberg et al. Soluble recombinant CD4—A potential therapeutic agent for HIV infection
Waldmann et al. The interleukin-2 receptor: a target for immunotherapy
US20030211470A1 (en) CD4-IgG2-based salvage therapy of HIV-1 infection
Hildreth et al. Production and characterization of monoclonal antibodies against pigtailed macaque (Macaca nemestrina) cell adhesion molecules
JPH05501116A (ja) エプスタイン・バーウイルス感染治療用のｂｃｒｆ１拮抗薬
WO9308278 Pharmaceutical applications

Legal Events

Date Code Title Description
FZDE Dead